Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax.
Adenosine Triphosphate
/ metabolism
Animals
Anthrax
/ blood
Antigens, Bacterial
/ blood
Bacillus anthracis
/ pathogenicity
Bacterial Toxins
/ blood
Case-Control Studies
Chromatography, High Pressure Liquid
/ methods
Cyclic AMP
/ biosynthesis
Disease Progression
Enzyme-Linked Immunosorbent Assay
Humans
Limit of Detection
Macaca mulatta
Polymerase Chain Reaction
Respiratory Tract Infections
/ blood
Tandem Mass Spectrometry
/ methods
Toxemia
/ blood
Adenylyl cyclase
Anthrax
Cyclic AMP
Edema toxin
HPLC
Mass spectrometry
Journal
Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
24
10
2018
accepted:
26
02
2019
revised:
06
02
2019
pubmed:
27
3
2019
medline:
25
6
2019
entrez:
27
3
2019
Statut:
ppublish
Résumé
Inhalation of Bacillus anthracis spores can cause a rapidly progressing fatal infection. B. anthracis secretes three protein toxins: lethal factor (LF), edema factor (EF), and protective antigen (PA). EF and LF may circulate as free or PA-bound forms. Both free EF (EF) and PA-bound-EF (ETx) have adenylyl cyclase activity converting ATP to cAMP. We developed an adenylyl cyclase activity-based method for detecting and quantifying total EF (EF+ETx) in plasma. The three-step method includes magnetic immunocapture with monoclonal antibodies, reaction with ATP generating cAMP, and quantification of cAMP by isotope-dilution HPLC-MS/MS. Total EF was quantified from 5PL regression of cAMP vs ETx concentration. The detection limit was 20 fg/mL (225 zeptomoles/mL for the 89 kDa protein). Relative standard deviations for controls with 0.3, 6.0, and 90 pg/mL were 11.7-16.6% with 91.2-99.5% accuracy. The method demonstrated 100% specificity in 238 human serum/plasma samples collected from unexposed healthy individuals, and 100% sensitivity in samples from 3 human and 5 rhesus macaques with inhalation anthrax. Analysis of EF in the rhesus macaques showed that it was detected earlier post-exposure than B. anthracis by culture and PCR. Similar to LF, the kinetics of EF over the course of infection were triphasic, with an initial rise (phase-1), decline (phase-2), and final rapid rise (phase-3). EF levels were ~ 2-4 orders of magnitude lower than LF during phase-1 and phase-2 and only ~ 6-fold lower at death/euthanasia. Analysis of EF improves early diagnosis and adds to our understanding of anthrax toxemia throughout infection. The LF/EF ratio may also indicate the stage of infection and need for advanced treatments.
Identifiants
pubmed: 30911800
doi: 10.1007/s00216-019-01730-4
pii: 10.1007/s00216-019-01730-4
pmc: PMC6988385
mid: NIHMS1067345
doi:
Substances chimiques
Antigens, Bacterial
0
Bacterial Toxins
0
anthrax toxin
0
Adenosine Triphosphate
8L70Q75FXE
Cyclic AMP
E0399OZS9N
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2493-2509Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Références
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52
pubmed: 18852857
Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6
pubmed: 6285339
Toxicon. 2001 Nov;39(11):1747-55
pubmed: 11595637
J Biol Chem. 2004 Jul 9;279(28):29427-35
pubmed: 15131111
Toxicon. 2008 Dec 1;52(7):824-8
pubmed: 18812184
Anal Chem. 2009 Jul 15;81(14):5935-41
pubmed: 19522516
Mol Aspects Med. 2009 Dec;30(6):456-66
pubmed: 19560486
Microb Genom. 2015 Nov 7;1(5):e000039
pubmed: 28348823
Anal Bioanal Chem. 2015 Apr;407(10):2847-58
pubmed: 25673244
J Bacteriol. 1994 Aug;176(16):5188-92
pubmed: 8051039
J Biol Chem. 1989 Nov 15;264(32):19379-84
pubmed: 2553737
Infect Immun. 2009 Aug;77(8):3432-41
pubmed: 19506008
Biochem J. 2007 Mar 15;402(3):405-17
pubmed: 17313374
Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;17:189-98
pubmed: 6328915
Molecules. 2011 Mar 14;16(3):2391-413
pubmed: 21403598
Infect Immun. 1988 May;56(5):1066-9
pubmed: 2895741
Infect Immun. 2007 Jun;75(6):2864-74
pubmed: 17371863
Trends Microbiol. 2014 Jun;22(6):317-25
pubmed: 24684968
J Clin Invest. 1975 Aug;56(2):339-45
pubmed: 168232
Emerg Infect Dis. 2014 Feb;20(2):310-4
pubmed: 24447456
Clin Infect Dis. 2007 Apr 1;44(7):968-71
pubmed: 17342650
PLoS One. 2013 Aug 28;8(8):e74474
pubmed: 24015319
Euro Surveill. 2008 Dec 18;13(51):null
pubmed: 19094916
PLoS Negl Trop Dis. 2013 Oct 03;7(10):e2468
pubmed: 24098822
Acta Endocrinol (Copenh). 1979 Jan;90(1):62-8
pubmed: 216209
J Clin Endocrinol Metab. 1977 Mar;44(3):514-9
pubmed: 190260
Int J Artif Organs. 1980 Jan;3(1):18-22
pubmed: 6243611
Anal Biochem. 2018 Feb 15;543:97-107
pubmed: 29224733
Am J Pathol. 2005 Nov;167(5):1309-20
pubmed: 16251415
Biochemistry. 2010 Jul 6;49(26):5494-503
pubmed: 20521845
Mol Aspects Med. 2009 Dec;30(6):406-12
pubmed: 19732789
Int J Biochem Cell Biol. 2007;39(1):20-4
pubmed: 17008119
Sci Rep. 2016 Mar 21;6:23346
pubmed: 26996161
Anal Chem. 2007 Nov 15;79(22):8463-70
pubmed: 17929949
Arch Dermatol Res. 1987;279 Suppl:S59-62
pubmed: 2821928
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13899-904
pubmed: 9811898